Therapeutic targeting of nuclear protein import in pathological cell conditions - PubMed (original) (raw)
Review
Therapeutic targeting of nuclear protein import in pathological cell conditions
Mirna N Chahine et al. Pharmacol Rev. 2009 Sep.
Abstract
Proteins enter the nucleus through the nuclear pore complex. Once in the nucleus, some proteins, such as transcriptional regulators, can turn genes on or off, and change the composition of the cell and its function to meet the demands of its environment. This process of protein import into the nucleus is highly controlled and regulated by the expression or function of single cargoes, transport receptors, or the transport channels themselves. Thus, these components of the import process have an impact on transport capacity, which subsequently affects gene expression, signal transduction, and cell growth and development. With such a key position in the process of cell growth, it is reasonable to hypothesize that alterations in nuclear protein transport may play an important role in pathological cell conditions that have abnormal cell growth as a central feature. Indeed, there are now sufficient data to demonstrate that alterations in nuclear protein transport participate in alterations in cell proliferation and hypertrophy. Further study is needed to provide definitive proof that changes in nuclear protein import directly participate in the pathogenesis of diseases such as hypertension, atherosclerosis, cancer, viral infection, and diabetes. However, the data to date have, on select occasions, led to a clear association of alterations in nuclear transport with disease states. Furthermore,this research has led to the important identification of new targets within the process of nuclear protein import that hold therapeutic promise to inhibit viral replication, to improve drug delivery during cancer therapy, and, in general, to modify cell growth and viability during disease conditions.
Similar articles
- RanGAP-mediated nuclear protein import in vascular smooth muscle cells is augmented by lysophosphatidylcholine.
Faustino RS, Stronger LN, Richard MN, Czubryt MP, Ford DA, Prociuk MA, Dibrov E, Pierce GN. Faustino RS, et al. Mol Pharmacol. 2007 Feb;71(2):438-45. doi: 10.1124/mol.105.021667. Epub 2006 Nov 14. Mol Pharmacol. 2007. PMID: 17105874 - Nuclear protein import is reduced in cells expressing nuclear envelopathy-causing lamin A mutants.
Busch A, Kiel T, Heupel WM, Wehnert M, Hübner S. Busch A, et al. Exp Cell Res. 2009 Aug 15;315(14):2373-85. doi: 10.1016/j.yexcr.2009.05.003. Epub 2009 May 12. Exp Cell Res. 2009. PMID: 19442658 - Targeted delivery to the nucleus.
Pouton CW, Wagstaff KM, Roth DM, Moseley GW, Jans DA. Pouton CW, et al. Adv Drug Deliv Rev. 2007 Aug 10;59(8):698-717. doi: 10.1016/j.addr.2007.06.010. Epub 2007 Jul 4. Adv Drug Deliv Rev. 2007. PMID: 17681634 Review. - Mechanisms of receptor-mediated nuclear import and nuclear export.
Pemberton LF, Paschal BM. Pemberton LF, et al. Traffic. 2005 Mar;6(3):187-98. doi: 10.1111/j.1600-0854.2005.00270.x. Traffic. 2005. PMID: 15702987 Review. - Ultrastructural nuclear import assay.
Zhong H, Shio H, Yaseen NR. Zhong H, et al. Methods. 2006 Aug;39(4):309-15. doi: 10.1016/j.ymeth.2006.07.012. Methods. 2006. PMID: 16935003
Cited by
- A jumbo problem: mapping the structure and functions of the nuclear pore complex.
Fernandez-Martinez J, Rout MP. Fernandez-Martinez J, et al. Curr Opin Cell Biol. 2012 Feb;24(1):92-9. doi: 10.1016/j.ceb.2011.12.013. Epub 2012 Feb 8. Curr Opin Cell Biol. 2012. PMID: 22321828 Free PMC article. Review. - Old Drugs for an Old Pathology? Drug Repurposing for Calcific Aortic Valve Disease.
Bartoli-Leonard F, Aikawa E. Bartoli-Leonard F, et al. Circ Res. 2021 Apr 30;128(9):1317-1319. doi: 10.1161/CIRCRESAHA.121.319149. Epub 2021 Apr 29. Circ Res. 2021. PMID: 33914606 Free PMC article. No abstract available. - Calcineurin dephosphorylates topoisomerase IIβ and regulates the formation of neuronal-activity-induced DNA breaks.
Delint-Ramirez I, Konada L, Heady L, Rueda R, Jacome ASV, Marlin E, Marchioni C, Segev A, Kritskiy O, Yamakawa S, Reiter AH, Tsai LH, Madabhushi R. Delint-Ramirez I, et al. Mol Cell. 2022 Oct 20;82(20):3794-3809.e8. doi: 10.1016/j.molcel.2022.09.012. Epub 2022 Oct 6. Mol Cell. 2022. PMID: 36206766 Free PMC article. - Discovery of a Novel Aminocyclopropenone Compound That Inhibits BRD4-Driven Nucleoporin NUP210 Expression and Attenuates Colorectal Cancer Growth.
Kondo H, Mishiro K, Iwashima Y, Qiu Y, Kobayashi A, Lim K, Domoto T, Minamoto T, Ogawa K, Kunishima M, Hazawa M, Wong RW. Kondo H, et al. Cells. 2022 Jan 18;11(3):317. doi: 10.3390/cells11030317. Cells. 2022. PMID: 35159127 Free PMC article. - Controlling subcellular delivery to optimize therapeutic effect.
Mossalam M, Dixon AS, Lim CS. Mossalam M, et al. Ther Deliv. 2010 Jul;1(1):169-93. doi: 10.4155/tde.10.8. Ther Deliv. 2010. PMID: 21113240 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical